Edwards Lifesciences Corp (EW)vsLENSAR Inc (LNSR)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
LNSR
LENSAR Inc
$5.74
0.00%
HEALTHCARE · Cap: $67.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 10824% more annual revenue ($6.30B vs $57.70M). LNSR leads profitability with a 50.9% profit margin vs 17.4%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
LNSR
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
-85.1%
Fair Value
$6.71
Current Price
$5.74
$0.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Every $100 of equity generates 36 in profit
Keeps 51 of every $100 in revenue as profit
Strong operational efficiency at 49.2%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 5.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 50.9% and operating margin at 49.2%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a growth stock while LNSR is a declining play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.87 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
LNSR generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 53/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?